ClinicalTrials.Veeva

Menu
C

Conquest Research | Winter Park, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Donanemab
Buntanetap
LY3002813
Remternetug
Teriflunomide
Ixekizumab
RTA 901
Dihydroergotamine
Tirzepatide
LY3454738

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

50 of 87 total trials

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approxi...

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo
Locations recently updated

The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn...

Enrolling
Early Alzheimers Disease
Drug: buntanetap/posiphen
Drug: Placebo

This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer...

Invitation-only
Alzheimer Disease 6
Cognitive Impairment
Device: Sensory Stimulation System (GS120) - Sham
Device: Sensory Stimulation System (GS120) - Active

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer´s Disease
Drug: Placebo (semaglutide)
Drug: Semaglutide

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer's Disease
Drug: Placebo (semaglutide)
Drug: Semagludtide

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Active, not recruiting
Alzheimer's Disease
Mental Disorders
Drug: Dexamethasone
Drug: Placebo

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheime...

Active, not recruiting
Alzheimer Disease
Cognitive Dysfunction
Drug: JNJ-63733657
Drug: Placebo

The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis...

Enrolling
Rheumatoid Arthritis
Drug: LY3541860

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: Placebo
Drug: LY3972406

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Enrolling
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic A...

Active, not recruiting
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

The main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's proc...

Enrolling
Hepatic Impairment
Healthy
Drug: Palovarotene

The goal of this clinical trial is to learn if a single knee injection of different doses (Dose A and Dose B) of an investigation product PCRX-201, f...

Enrolling
Osteoarthritis (OA) of the Knee
Biological: Enekinragene Inzadenovec (PCRX-201)
Biological: Placebo

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Active, not recruiting
Alzheimer's Disease (AD)
Drug: Placebo
Drug: ABBV-916

The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive a...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: sabirnetug

The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic...

Enrolling
Chronic Migraine
Other: Placebo
Biological: Botulinum toxin type A

The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic...

Enrolling
Episodic Migraine
Other: Placebo
Biological: Botulinum toxin type A

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab...

Active, not recruiting
Parkinsons Disease
Drug: Placebo
Drug: Prasinezumab

Trial sponsors

Lilly logo
Novartis logo
AbbVie logo
A
Ipsen logo
Biogen logo
Biohaven logo
Boehringer Ingelheim logo
Cognito Therapeutics logo
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems